Aim Bulletin
Hutchmed publishes positive sovleplenib trial results
By Josh White
Date: Monday 17 Jun 2024
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
The AIM-traded firm said sovleplenib, a novel, selective oral inhibitor targeting spleen tyrosine kinase (Syk), was evaluated for treating adult patients with primary immune thrombocytopenia (ITP) in China.
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
Article Archive
You are here: news
